Smaller pharmaceutical firms hesitate to develop generic drugs

Published: 2012-02-10 06:59:00

Updated: 2012-02-10 06:59:00

Korea’s small- and mid-sized drug makers have rolled up their sleeves to tighten their belts as the government’s massive price-cut plan is expected to deal the hardest blow to their revenue.

Given the unfavorable factor, these firms are hesitating to release generic products to the market, say...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK